Efficacy and safety of Jak inhibitor in the treatment of moderate and severe atopic dermatitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061505

Enrollment

Unknown

Registered

2022-06-27

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Experimental group:Jak inhibitors

Eligibility

Sex/Gender

All

Age

12 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 12 to 75 years old, weight >= 40kg; 2. Diagnose AD according to Williams AD diagnostic criteria; 3. >=10% BSA, EASI >=16; 4. Voluntary signing of informed consent: For patients under 18 years old, I need to agree to participate in this research, and their parents/legal guardians must sign a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of thrombotic events (including deep vein thrombosis, pulmonary embolism, and cerebrovascular diseases), and patients with other known internal conditions that may easily lead to hypercoagulability; 2. Pregnant or lactating patients; 3. Those who are contraindicated by Jak inhibitors.

Design outcomes

Primary

Measure	Time frame
Eczema Area and Severity Index (EASI) score;Investigator’s Global Assessment (IGA) score;Itching Visual Analogue Scale (VAS) score;Dermatology Life Quality Index (DLQI);Children Dermatology Life Quality Index (CDLQI);Patient-Oriented Eczema Measure (POEM);	—

Countries

China

Contacts

Public ContactLi Jingyi

West China Hospital, Sichuan University

ljy7733@163.com+86 18980605704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026